We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Bextra

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Bextra

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Bextra is approved to treat the signs and symptoms of osteoarthritis (OA), adult rheumatoid arthritis (RA) and the treatment of pain associated with menstrual cramping. Bextra has previously been approved for relief from arthritis pain. Bextra is a once-daily treatment in an oral tablet formulation.

    More than 23 million Americans suffer from some form of arthritis. The most prevalent is OA, which affects approximately 21 million Americans. This chronic disorder is characterized by the degeneration of joint cartilage and bone, which can lead to severe pain and stiffness. RA, which affects joint lining, cartilage and bone, affects over two million Americans.

    Clinical Results

    The approval of Bextra is supported by results from clinical studies lasting from three to six months. In five double-blind trials with 3,918 subjects with OA of the knee or hip, Bextra was significantly superior to placebo and comparable to a naproxen control, in treating pain and stiffness and improving functional measures. In four double-blind trials with 3,444 subjects with RA, Bextra demonstrated significantly better results than placebo and comparable results to naproxen in improving the tenderness and number of swollen joints and the level of pain. Bextra was evaluated for treatment of menstrual pain in two placebo-controlled studies. The onset, magnitude and duration of analgesic effect of a 20 mg dose of Bextra was comparable to a 500 mg dose of naproxen.

    In all studies, Bextra was overall well tolerated and exhibited a significantly better gastrointestinal safety profile than other conventional nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen, ibuprofen and diflonac.

    Side Effects

    Adverse events associated with the use of Bextra may include (but are not limited to) the following:


    • Dyspepsia
    • Headache
    • Abdominal pain
    • Nausea
    • Diarrhea

    Mechanism of Action

    Bextra (valdecoxib) is an NSAID that exhibits anti-inflammatory, analgesic and antipyretic properties. These effects are due to the inhibition of COX-2, which in turn inhibits prostaglandin synthesis.

    Approval Date: 2001-11-01
    Date Created: 2002-02-14 12:00:00
    Company Name: Pharmacia, Pfizer
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing